EXICURE, INC. Cash and Cash Equivalents, Period Increase (Decrease)
EXICURE, INC. (XCUR) reported Cash and Cash Equivalents, Period Increase (Decrease) of $22.19 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-10.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-03-10
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was -$21.93M.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $53.22M, a 231.24% increase year-over-year.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$5.02M.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$4.07M.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $22.19M, a 4303.17% increase from fiscal 2018.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $504.00K, a 91.79% decline from fiscal 2017.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $6.14M, a 588.45% increase from fiscal 2016.
- EXICURE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $892.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$21.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $31.29M derived: sum of 2 quarters · filed 2020-03-10 | $26.26M derived: sum of 3 quarters · filed 2020-03-10 | $22.19M 10-K · filed 2020-03-10 |
| 2019-09-30 | $53.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $48.20M derived: sum of 2 quarters · filed 2019-11-07 | $44.12M 10-Q · filed 2019-11-07 | $37.95M derived: sum of 4 quarters · filed 2020-03-10 |
| 2019-06-30 | -$5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$9.09M 10-Q · filed 2019-08-08 | -$15.27M derived: sum of 3 quarters · filed 2020-03-10 | $795.00K derived: sum of 4 quarters · filed 2020-03-10 |
| 2019-03-31 | -$4.07M 10-Q · filed 2019-05-08 | -$10.25M derived: sum of 2 quarters · filed 2020-03-10 | $5.82M derived: sum of 3 quarters · filed 2020-03-10 | $1.07M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-12-31 | -$6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $9.89M derived: sum of 2 quarters · filed 2020-03-10 | $5.14M derived: sum of 3 quarters · filed 2020-03-10 | $504.00K 10-K · filed 2020-03-10 |
| 2018-09-30 | $16.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $11.32M derived: sum of 2 quarters · filed 2019-11-07 | $6.68M 10-Q · filed 2019-11-07 | $9.51M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$9.38M 10-Q · filed 2019-08-08 | -$6.56M derived: sum of 3 quarters · filed 2019-09-23 | $7.55M derived: sum of 4 quarters · filed 2019-09-23 |
| 2018-03-31 | -$4.64M 10-Q · filed 2019-05-08 | -$1.81M derived: sum of 2 quarters · filed 2019-09-23 | $12.30M derived: sum of 3 quarters · filed 2019-09-23 | |
| 2017-12-31 | $2.83M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $16.94M derived: sum of 2 quarters · filed 2019-09-23 | $6.14M 10-K/A · filed 2019-09-23 | |
| 2017-09-30 | $14.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $3.31M 10-Q · filed 2018-11-06 | ||
| 2017-08-31 | -$5.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-09-12 | -$4.48K 10-Q · filed 2017-09-12 | ||
| 2017-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$10.80M 10-Q · filed 2018-08-06 | ||
| 2017-05-31 | $1.17K 10-Q · filed 2017-07-11 | |||
| 2017-03-31 | -$7.20M 10-Q · filed 2018-05-15 | -$1.64M derived: sum of 2 quarters · filed 2018-05-15 | ||
| 2016-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $892.00K 10-K · filed 2018-03-09 | ||
| 2016-09-30 | -$4.66M 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |